Core advanced pharmacist e-Portfolio: JCP example

Journal club presentation (JCP) example

Purpose

Evaluates the individual’s ability to present at a journal club, demonstrating knowledge of research methods and critical evaluation skills.

Examples of when it can be used

Providing a contextualised summary of a new study to a multidisciplinary group, critiquing the strengths and limitations of the study, consider how it add to the existing knowledge base.

Instructions

Provide feedback on what the pharmacist did well and areas for development.
The overall rating should reflect the expected level of an advanced pharmacist as defined in the curriculum.
‘Not applicable’ means that the pharmacist did not cover the identified area as it was not within the context of the procedure or case.
‘Below’ means that either the pharmacist did not cover the identified area to a competent level or it was not demonstrated at all, and should have been.

Collaborator Assessment
Introduces the topic
Describes the background to the topic, the rational for and clinical relevance of the study question, and a summary of existing literature *	Below☐	Meets☐	Exceeds☒	Not applicable☐
Comments: strengths and/or areas for development * As our practice lead for diabetes, the pharmacist was able to provide all of the relevant context underpinning this paper, presenting not just the national picture but also local context, and how this would impact on our local population.
Study methodology and results
Clearly describes the aim, study population including inclusion/exclusion criteria, the intervention, outcomes, and statistical analysis (as appropriate to study design) *	Below☐	Meets☒	Exceeds☐	Not applicable☐
Comments: strengths and/or areas for development * The pharmacist provided a clear summary of the study methodology, the population included (and excluded), and the benefits and side effects associated with the medicines.
Analysis and critique
Describes strengths/weaknesses of the paper and their own perspective on the validity of the study results / authors’ conclusions. *	Below☐	Meets☒	Exceeds☐	Not applicable☐
Comments: strengths and/or areas for development * The pharmacist was able to critique the trial data, describing the validity of the author’s conclusions, and also identifying potential issues (e.g. real world practice vs trial conditions, the complexity of the local population compared to the trial population, etc.).
Implications for practice
Describes implications for current / future clinical practice and research. *	Below☐	Meets☐	Exceeds☒	Not applicable☐
Comments: strengths and/or areas for development * The pharmacist really understood how this evidence and the potential introduction of this new medicine impacted on local practice. She had already updated our local diabetes protocol, and clearly articulated how this would be implemented.
Presentation
Presents in a clear and concise way, appropriately uses visual material, conveys their critical evaluation of the topic into a concise and flowing presentation. *	Below☐	Meets☐	Exceeds☒	Not applicable☐
Comments: strengths and/or areas for development * The pharmacist demonstrated her ability to describe complex information in a way that was understandable for the mixed audience (including GPs, practice nurses, AHPs, and a range of students). She was articulate and clear, and managed questions extremely well.She appeared confident and knowledgeable throughout.

Summary of Assessment
Overall rating * Based on your observation of this presentation, rate the overall level at which the pharmacist has shown that they are performing	Below the level expected of an advanced pharmacist	☐
	Working towards the level expected of an advanced pharmacist	☐
	Meets the level expected of an advanced pharmacist	☒
Other relevant comments or feedback	A really strong presentation and great demonstration of clinical, critical analysis, and presentation skills. The pharmacist has developed significantly over the last 12 months, and is emerging as a clinical expert in diabetes.
Agreed action(s)	The pharmacist has been asked to repeat the presentation across the region and will lead on the implementation of the new medicine for our local area.
Learner’s reflection Describe what you have learned. How will it change your practice in the future?	I was really pleased with the feedback from Dr Khan, who leads on long-term conditions for our region, and regularly reviews and critically appraises clinical trials.Whilst I have grown in confidence in my clinical practice around diabetes, I had not undertaken any critical appraisal since my postgraduate diploma. I accessed some learning materials which helped to refresh my knowledge. I was really happy that I was able to present the trial data confidently and competently, and answer a range of questions including some on the trial methodology.I’m looking forward to presenting the data to a wider audience.

Collaborative supported e-Portfolio programme to advanced pharmacist practice in England

This was originally published when the organisation was the Royal Pharmaceutical Society, some updates will follow soon. Developed in collaboration with the RPS, NHSE WT&E Centre for Advancing Practice and CPPE. Provides a supported professional development programme to advanced pharmacist practice for eligible pharmacists in England, funded by NHSE WT&E’s Centre for Advancing Practice 300 funded places for pharmacists in 2023-2024 Recognises the quality assurance of the advanced practice education, training, and experience of pharmacists practicing as advanced practitioners. Who is eligible for this programme? To be eligible for this programme, pharmacists must meet NHSE WT&E’s Centre of Advancing Practice criteria and the requirements to meet the Core Advanced curriculum outcomes. To be eligible, you must: Be a pharmacist practising in England delivering NHS services Working in an advanced patient-focused pharmacist role Be working at, or close to, an advanced level of pharmacist practice (as defined in the Core Advanced curriculum)1 Be an active prescriber if working in a patient-facing role Be currently leading, or managing other team members in the workplace Be undertaking quality improvement and/or research activities to improve healthcare outcomes at a team and/or service level Have agreement from your employer to support you with the programme by providing high-quality practice supervision, including supporting with work-based supervised learning events (SLEs). 1 For those working in general practice, this may include a completed Statement of Assessment and Progression from a CPPE’s national PCPEP training pathway or equivalent. What is the programme based on? The programme is based on the RPS Core Advanced curriculum, which is fully aligned to the NHSE WT&E Advanced Clinical Practice framework. Candidates will need to develop a portfolio of evidence against the RPS Core Advanced curriculum outcomes using the Core Advanced e-Portfolio. What support will I receive to develop my portfolio? Programme support is provided by CPPE. If you are assigned a place on the programme, you will: Be assigned a dedicated educational supervisor from CPPE who will support you remotely developing your portfolio Have a 90-minute learning needs analysis discussion with your educational supervision with the development of an individual development plan to address any learning or experiential deficits Have two remote 1-2-1 meetings with your educational supervisor to discuss the quality of your evidence Receive peer-to-peer support to develop your e-portfolio evidence through remote group tutorials. What will the final sign-off assessment look like? The programme covers a funded final sign off assessment. Your portfolio assessment will be assessed by an Advanced Pharmacist Competence Committee (APCC) as described in the programme of assessment section of the Core Advanced curriculum. What do I get if I successfully complete the programme? Those who successfully complete the programme and credentialing assessment through the RPS will receive the following dual award: The RPS Core Advanced credential, recognising you as an advanced pharmacist. If you are an RPS member, this means you will be able to use the modified membership affix: MRCPharm(Advanced) or FRCPharm(Advanced) NHSE WT&E’s Centre for Advancing Practice’s ‘Advanced’ digital badge, demonstrating the quality assurance of your advanced practice preparation to patients, families, carers, and other healthcare professionals. This will mean you will be recognised as having equivalence in terms of level of advanced practice as those who have completed the alternative NHSE WT&E supported e-Portfolio (supported) route or a NHSE WT&E-accredited advanced practice programme. How do I sign up to be assigned to a cohort on the programme? To sign up for the programme, you need to register your interest through the CPPE website as well as through the NHSE WT&E portal. You will then be contacted by an education supervisor to arrange a learning needs analysis meeting. After this meeting, there will be a discussion about which cohort you will join. In the meantime, we recommend that you read the getting started guidance. What is the difference between an advanced pharmacist and an advanced practitioner? >In summary, advanced pharmacists have advanced pharmaceutical clinical capabilities in addition to advanced non-clinical capabilities. The role of an advanced pharmacist could not be safely delivered by an individual from another professional group. An advanced practitioner focuses on clinical assessment skills for managing undifferentiated patient presentations within speciality areas of practice, such as emergency medicine or general practice. These roles draw on individuals' professional expertise and can be safely undertaken by individuals drawn from a range of multi-professional backgrounds. Both advanced pharmacists and other advanced practitioners practise at an advanced level and deliver complex care autonomously. Both are also experienced practitioners across the four pillars of practice. For more detail, see section 2.3 of the Core Advanced curriculum. What if I am not near to or at the advanced level of practice and/or not eligible for the programme? If you do not currently meet the eligibility criteria for the programme but would like to commence your journey towards advanced practice credentialing, please refer to the getting started guidance. 2024 CPPE pathway submission dates Submission window opensFinal submission deadlineAnticipated outcome dateApplication 17 January 202414 January 202427 February 2024Application 24 February 202411 February 202426 March 2024Application 37 April 202414 April 202428 May 2024Application 45 May 202412 May 202425 June 2024Application 54 August 202411 August 202424 September 2024 CPPE advanced credentialing support programme webpage Centre for Advancing Practice appeals and complaints procedure

Core advanced pharmacist e-Portfolio: CbD example

Case based Discussion (CbD) example Purpose Retrospectively evaluates the individual’s input into patient care. A structured discussion is undertaken remotely from the patient and is used to explore clinical reasoning, decision making and application of clinical knowledge in practice. Examples of when it can be used Discussion of a highly complex case where you have had to identify and implement treatment options where evidence is limited or ambiguous. Discussion of a case where you have had to apply clinical reasoning for people with complex physical, phycological or social needs Instructions Provide feedback on what the pharmacist did well and areas for development. The overall rating should reflect the expected level of an advanced pharmacist as defined in the curriculum. ‘Not applicable’ means that the pharmacist did not cover the identified area as it was not within the context of the procedure or case. ‘Below’ means that either the pharmacist did not cover the identified area to a competent level or it was not demonstrated at all, and should have been. CbDTitle *Discussion about the autonomous management of a patient with hypertension unresponsive to treatmentDate of assessment *5.9.2022 Collaborator DetailsCollaborator name *K RCollaborator emailOnly required for sending ticketed [email protected] position *Practice NurseCollaborator profession *NurseCollaborator declaration *I can confirm I have read the RPS collaborator guidance and have the appropriate experience to complete this assessment. I confirm I have completed the assessment objectively and independently.Yes ☒ Details of CaseSummary of case(s)* I presented a case from my hypertension clinic to one of the local senior / very experienced practice nurses. The case involved the diagnosis and management of Conn's Syndrome (Primary Aldosteronism), in the context of a patient with resistant hypertension.Clinical setting *General practice clinicFocus of clinical encounter *History ☒ Diagnosis ☒ Management ☒ Information provision ☐Level of complexity*Low ☐ Medium ☒ High ☐ Collaborator AssessmentProfessionalismIs accountable and responsible for own decisions. Works within ethical guidelines and legal frameworks. Actively practices honesty and integrity. Works safely within own level of competence, knows when to escalate or refer *Below☐Meets☐Exceeds☒Not applicable☐Comments: strengths and/or areas for development *Perfect! No concerns at all! I have worked with the pharmacist for many years and their professionalism is first rate.Clinical reasoningGathers focused information relevant to the person and their condition. Performs appropriate clinical examinations and assessments. Requests and interprets appropriate investigations and examinations. Makes an appropriate working diagnosis or decision. Applies the evidence base and professional judgement to support holistic person centred care. *Below☐Meets☐Exceeds☒Not applicable☐Comments: strengths and/or areas for development *The pharmacist presented the case really well, including the past medical history, clinical signs and symptoms, and the beliefs and desires of the patient.The pharmacist had a clear justification for suspecting of Conn's Syndrome (Primary Aldosteronism) in this patient, including resistant hypertension (BP 175/100mmHg) despite treatment with the three blood pressure lowering medications, good medication adherence (the pharmacist confirmed this via both the patient and the re-ordering history), and hypokalaemia (potassium 3.5 mmol/l). The pharmacist autonomously ordered renin and aldosterone levels for the patients on two occasions (both of which showed an aldosterone:renin ratio of greater than 30) and a salt loading test. These tests had confirmed the presence of primary hyperaldosteronism. Clinical managementApplies clinical knowledge and skills to manage options and medicines appropriately and safely. Assesses and critically evaluates appropriate information to make evidence-based decisions. Makes appropriate use of referrals and prioritises care appropriately. *Below☐Meets☒Exceeds☐Not applicable☐Comments: strengths and/or areas for development *Following the confirmation of Conn's Syndrome, and given the presence of resistant hypertension, the pharmacist was able to justify their choice for starting the patient on Spironolactone (i.e. PATHWAY-2 trial data). The pharmacist involved the patient in this decision as an equal partner, educated and safety netted them on potential ADRs and red flags, and then put an appropriate follow-up plan in place for BP and U&E monitoring.Organisation & efficiencyEffectively, efficiently and safely manages multiple priorities. Manages own time and workload calmly. Organises and delegates tasks appropriately to optimise effectiveness within the pharmacy and wider team, to enhance patient care. *Below☐Meets☒Exceeds☐Not applicable☐Comments: strengths and/or areas for development *Worked excellently with all stakeholders, in an efficient and respectful manner. Also used the MDT appropriately where needed – e.g. phlebotomy services etc. Summary of AssessmentOverall rating *Based on your discussion, rate the overall level at which the pharmacist has shown that they are performing Below the level expected of an advanced pharmacist☐Working towards the level expected of an advanced pharmacist☐Meets the level expected of an advanced pharmacist☒Other relevant comments or feedbackReally good example of appropriate autonomous work.Agreed action(s)None needed.Learner's reflectionDescribe what you have learned. How will it change your practice in the future? It’s useful to discuss cases – in particular where I have been able to use additional diagnostic tests and manage the person’s care through to completion. AttachmentsUpload a file to support this record MappingsConsider what learning outcome(s) this record provides evidence for and map to all that apply2.1 Delivers care using advanced pharmaceutical knowledge and skills for individuals and/or groups with highly complex needs, including where evidence is limited or ambiguous.2.2 Undertakes a holistic clinical review of individuals with complex needs, using a range of assessment methods, appropriately adapting assessments and communication style based on the individual.2.3 Demonstrates effective clinical reasoning skills, making autonomous, evidence informed, person-centred decisions about treatment for individuals or groups with complex clinical needs, managing risk in the presence of significant uncertainty.

Details of Paper(s)
Summary of paper(s) presented *	I presented a paper on the use of a new long-acting injectable medicine for diabetes.It had a positive impact on diabetes control, weight, and cardiovascular outcomes.The introduction of this medicine within our practices will require additional monitoring, and an update of our internal diabetes protocols.
Clinical setting(s) *	General Practice

JCP
Title *	Journal club presentation
Date of assessment *	04/09/2022